$TRIP Are TripAdvisor (TRIP) and Yelp (YELP) Overpriced? By Alan Farley Updated Feb 8, 2021 Yelp Inc. (YELP) reports fourth quarter 2020 earnings after Tuesday's closing bell, while TripAdvisor, Inc. (TRIP) steps to the plate next week. Both review sites have worked their way back to pre-pandemic highs in recent months, even though millions of folks are still eating three-course dinners out of plastic boxes and haven't seen the inside of an airplane for a year or more. As a result, these issues may now be overpriced, exposing them to strong sell-the-news reactions. Key Takeaways Yelp reports earnings on Tuesday, while TripAdvisor reports on Feb. 18. Both stocks have bounced back to pre-pandemic levels. Both were stuck in multi-year downtrends prior to the pandemic and now look overpriced. Yelp stock could drop into the mid- to upper $20s. Three vaccines are slowly working their way around the planet, while two new applicants should get approval in the next few weeks. Even so, the normalcy expected by many analysts during the summer travel season may be too optimistic, undermining Yelp and TripAdvisor income for the second year in a row. In addition, COVID-19 will leave behind trust issues and emotional scars, potentially keeping many folks out of restaurants and off airplanes until at least 2022. Both portals rely on advertising revenue that is still well below 2019 levels. They also book income through cross-selling, capturing commissions when contractors, restaurants, and travel are booked through their sites. Heavy competition limited that income stream before the pandemic, as well as a growing backlash due to deceptive pricing. Food delivery services are running into similar issues right now, with restaurants offering discounts for direct orders. These stocks were laggards prior to the pandemic, topping out in 2014 and entering declines that were still in force in February 2020. That's reason enough to act cautiously ahead of earnings, when these companies are expected to report another quarter of shrinking revenue. Wall Street has baked this uncertainly into Yelp's "Hold" rating, based upon three "Buy," six "Hold," and two "Sell" recommendations. In addition, the stock is trading less than $2 below the Street-high $37 target. A laggard is a stock or security that is underperforming relative to its benchmark or peers. A laggard will have lower-than-average returns compared to the market. A laggard is the opposite of a leader.

$GOSS Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data relevant to GB1275 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), to be held virtually from November 9-14, 2020. This includes clinical and biomarker data from the ongoing GB1275 Phase 1/2 clinical trial, KEYNOTE-A36, in advanced solid tumors and corresponding presentations from Johanna Bendell, M.D. and Wells Messersmith, M.D. Details for presentations related to GB1275, a CD11b modulator in clinical development for the treatment of solid tumors, are as follows: Poster Title: Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors Poster / Abstract Number: 388 Presenting Author: Johanna Bendell, M.D. Poster Title: Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors Poster / Abstract Number: 389 Presenting Author: Wells Messersmith, M.D. Posters can be accessed on the SITC website on Monday, November 9th at 8:00 a.m. EST. The posters will also be made available in the "Posters and Publications" section of the Gossamer Bio website at gossamerbio.com.